Study of DCR-A1AT in Healthy Adult Volunteers
A Phase 1 Single Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered Belcesiran in Healthy Adult Volunteers
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Listed as NCT04174118, this PHASE1 trial focuses on Alpha 1-Antitrypsin Deficiency and remains completed. Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Dec 2024 — Present [monthly]
Completed PHASE1
-
Oct 2024 — Dec 2024 [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Sep 2022 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
For direct contact, visit the study record on ClinicalTrials.gov .